Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 6/20 | 0.48 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.48 |
| ▸ | ADRA1B known ✓ | P35368 | 6/20 | 0.48 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.47 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.47 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.47 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL3952300 | 1.00 | PKM (0.51) | PKMADRA1DADRA1AADRA1BADRB2 | |
| SCHEMBL1412240 | 0.90 | ADRA1D (0.55) | PKMADRA1DADRA1AADRA1BADRB2 | |
| SCHEMBL3948856 | 0.90 | ADRA1D (0.55) | PKMADRA1DADRA1AADRA1BADRB2 | |
| SCHEMBL13880696 | 0.90 | ADRA1D (0.55) | PKMADRA1DADRA1AADRA1BADRB2 | |
| SCHEMBL29519545 | 0.90 | ADRA1D (0.55) | PKMADRA1DADRA1AADRA1BADRB2 | |
| SCHEMBL1412238 | 0.90 | ADRA1D (0.55) | PKMADRA1DADRA1AADRA1BADRB2 | |
| Hydrochloric Acid SCHEMBL6684814 | 0.88 | ADRA1D (0.54) | PKMADRA1DADRA1AADRA1BADRB2 | |
| Hydrochloric Acid SCHEMBL3939257 | 0.88 | ADRA1D (0.54) | PKMADRA1DADRA1AADRA1BADRB2 | |
| SCHEMBL28868425 | 0.83 | ADRA1D (0.54) | PKMADRA1DADRA1AADRA1BADRB2 | |
| SCHEMBL28868427 | 0.83 | ADRA1D (0.54) | PKMADRA1DADRA1AADRA1BADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603866-B1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LTD (IN) | 2009-04-29 | — | — | EP | disclosed |
| US-20080033208-A1 | Process for Manufacturing Optically Pure (R) or (S)-5-(2-Aminopropyl)-2-Methoxybenzene Sulfonamide | CADILA HEALTHCARE LIMITED (IN) | 2008-02-07 | — | — | US | disclosed |
| EP-1720830-A1 | PROCESS FOR MANUFACTURING OPTICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENE SULFONAMIDE | CADILA HEALTHCARE LTD. (IN) | 2006-11-15 | — | — | EP | disclosed |
| US-20060173214-A1 | Process for the preparation of enantiomerically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide | CADILA HEALTHCARE LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
| EP-1603866-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LTD. (IN) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005080323-A1 | PROCESS FOR MANUFACTURING OPTICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENE SULFONAMIDE | CADILA HEALTHCARE LIMITED (IN) | 2005-09-01 | — | — | WO | disclosed |
| WO-2004058694-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LIMITED (IN) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033208-A1 | Process for Manufacturing Optically Pure (R) or (S)-5-(2-Aminopropyl)-2-Methoxybenzene Sulfonamide | SRR, SRMS, AASDHPPT | ADRA1D 1822/4885ADRA1A 1878/4885ADRA1B 795/4885 |
| US-20060173214-A1 | Process for the preparation of enantiomerically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide | SRMS, SPR, SRR | ADRA1D 1701/4885ADRA1A 2452/4885ADRA1B 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.